This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2029-12-30

Target enrollment:

Participant gender:

This is a phase II, open-label, multicentre study of Zanubrutinib-containing regimens in patients with newly diagnosed mantle cell lymphoma.

PHASE2

Henan Cancer Hospital

obinutuzumab
zanubrutinib